Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-232 in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06801236Phase 1Recruiting
- Sponsor
- Acerand Therapeutics
- Start
- May 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of ACE-232 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Acerand Therapeutics. Primary endpoints: Number of patients experiencing adverse events (AEs)/serious adverse events (SAEs) at 37 months, Number of patients experiencing dose limiting toxicity (DLT) at 28 days and 1 more. Started May 2025; status: recruiting.
02
Drugs
ACE-232
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06801236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06801236.